Health check

6 Sep 2016 By Sara Silver

Fresh from splitting off its industrial arm, the healthcare giant is buying molecular tester Cepheid. Cost cuts cover barely half the 54 pct premium and investors aren’t buying promises of extra revenue. CEO Tom Joyce’s claims of greater efficiency and growth are falling flat.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)